Ghent University Academic Bibliography

Advanced

Modern treatment for nasopharyngeal carcinoma: current status and prospects

Sylvie Rottey UGent, Indira Madani UGent, PHILIPPE DERON UGent and Simon Van Belle UGent (2011) CURRENT OPINION IN ONCOLOGY. 23(3). p.254-258
abstract
Purpose of review : In this article, we focus on the role of Epstein-Barr virus in the management of nasopharyngeal cancer, intensity-modulated radiotherapy, adjuvant and neoadjuvant chemotherapy, and targeted therapy. Recent findings : Epstein-Barr virus DNA clearance has recently been studied for prediction of tumor response and survival. Patients with a short t1/2 of plasma Epstein-Barr virus DNA clearance had significantly higher responses and survival than those with long t1/2. Intensity-modulated radiotherapy, delivering higher doses to the tumor, results in improved local control and overall survival at lower treatment-induced toxicity. Recent reports show that re-planning during the course of radiotherapy could influence outcome and toxicity. The use of newer platinum compounds and combinations with taxanes in adjuvant and neoadjuvant setting have been investigated in phase II trials. They demonstrate acceptable toxicity profiles and promising treatment outcomes. However, antiepidermal growth factor receptor and antivascular endothelial growth factor receptor agents do not show important responses in metastatic disease and when combined with radiotherapy, toxicity is of concern. Summary : Epstein-Barr virus DNA has a potential as a risk stratification marker. Intensity-modulated radiotherapy is standard treatment and adaptive radiotherapy with re-planning has to be considered. Uncertainties on adjuvant/neoadjuvant chemotherapy should be addressed in well designed randomized trials. Currently, the role of targeted agents is not well defined.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (review)
publication status
published
subject
keyword
PHASE-II TRIAL, INTENSITY-MODULATED RADIOTHERAPY, CHEMOTHERAPY, CONCURRENT, CANCER, chemoradiotherapy, Epstein-Barr virus, targeted therapy, nasopharyngeal carcinoma, intensity-modulated radiotherapy
journal title
CURRENT OPINION IN ONCOLOGY
Curr Opin Oncol
volume
23
issue
3
pages
254 - 258
Web of Science type
Review
Web of Science id
000289507900004
JCR category
ONCOLOGY
JCR impact factor
4.101 (2011)
JCR rank
46/190 (2011)
JCR quartile
1 (2011)
ISSN
1040-8746
DOI
10.1097/CCO.0b013e328344f527
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1998721
handle
http://hdl.handle.net/1854/LU-1998721
date created
2012-01-20 15:15:24
date last changed
2012-01-26 11:22:18
@article{1998721,
  abstract     = {Purpose of review : In this article, we focus on the role of Epstein-Barr virus in the management of nasopharyngeal cancer, intensity-modulated radiotherapy, adjuvant and neoadjuvant chemotherapy, and targeted therapy. 
Recent findings : Epstein-Barr virus DNA clearance has recently been studied for prediction of tumor response and survival. Patients with a short t1/2 of plasma Epstein-Barr virus DNA clearance had significantly higher responses and survival than those with long t1/2. Intensity-modulated radiotherapy, delivering higher doses to the tumor, results in improved local control and overall survival at lower treatment-induced toxicity. Recent reports show that re-planning during the course of radiotherapy could influence outcome and toxicity. The use of newer platinum compounds and combinations with taxanes in adjuvant and neoadjuvant setting have been investigated in phase II trials. They demonstrate acceptable toxicity profiles and promising treatment outcomes. However, antiepidermal growth factor receptor and antivascular endothelial growth factor receptor agents do not show important responses in metastatic disease and when combined with radiotherapy, toxicity is of concern. 
Summary : Epstein-Barr virus DNA has a potential as a risk stratification marker. Intensity-modulated radiotherapy is standard treatment and adaptive radiotherapy with re-planning has to be considered. Uncertainties on adjuvant/neoadjuvant chemotherapy should be addressed in well designed randomized trials. Currently, the role of targeted agents is not well defined.},
  author       = {Rottey, Sylvie and Madani, Indira and DERON, PHILIPPE and Van Belle, Simon},
  issn         = {1040-8746},
  journal      = {CURRENT OPINION IN ONCOLOGY},
  keyword      = {PHASE-II TRIAL,INTENSITY-MODULATED RADIOTHERAPY,CHEMOTHERAPY,CONCURRENT,CANCER,chemoradiotherapy,Epstein-Barr virus,targeted therapy,nasopharyngeal carcinoma,intensity-modulated radiotherapy},
  language     = {eng},
  number       = {3},
  pages        = {254--258},
  title        = {Modern treatment for nasopharyngeal carcinoma: current status and prospects},
  url          = {http://dx.doi.org/10.1097/CCO.0b013e328344f527},
  volume       = {23},
  year         = {2011},
}

Chicago
Rottey, Sylvie, Indira Madani, PHILIPPE DERON, and Simon Van Belle. 2011. “Modern Treatment for Nasopharyngeal Carcinoma: Current Status and Prospects.” Current Opinion in Oncology 23 (3): 254–258.
APA
Rottey, S., Madani, I., DERON, P., & Van Belle, S. (2011). Modern treatment for nasopharyngeal carcinoma: current status and prospects. CURRENT OPINION IN ONCOLOGY, 23(3), 254–258.
Vancouver
1.
Rottey S, Madani I, DERON P, Van Belle S. Modern treatment for nasopharyngeal carcinoma: current status and prospects. CURRENT OPINION IN ONCOLOGY. 2011;23(3):254–8.
MLA
Rottey, Sylvie, Indira Madani, PHILIPPE DERON, et al. “Modern Treatment for Nasopharyngeal Carcinoma: Current Status and Prospects.” CURRENT OPINION IN ONCOLOGY 23.3 (2011): 254–258. Print.